ChenoCentryx (CCXI) Files $69M IPO

ChenoCentryx, Inc. (Nasdaq: CCXI), filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $69 million. ChenoCentryx plans to list on the Nasdaq Global Market under the ticker "CCXI."

The offering is being made through J.P. Morgan, Citi, and Cowen and Company.

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• AES prices $1 billion senior notes offering with 2029 and 2033 maturities
• Marvell names Dan Durn as CFO effective June 15, 2026
• SEC proposes eliminating Order Protection Rule for trading